Meloxicam Use in Elderly Patients with Moderate Renal Impairment

Risk Assessment and Guideline Recommendations

The International Society of Geriatric Oncology recommends that coadministration of known nephrotoxic drugs such as NSAIDs or COX-2 inhibitors should be avoided or minimized in elderly patients with renal impairment, as they face significantly increased risk of NSAID-associated renal impairment 1, 2
Elderly patients experience age-related renal decline of approximately 1% per year after age 30-40, meaning a 70-year-old may have lost 40% of baseline renal function, and drugs eliminated via the kidneys result in reduced clearance in declining renal function, necessitating careful consideration 3
Ensure adequate hydration status before initiating meloxicam therapy, and baseline renal function should be documented with a plan for monitoring, according to the International Society of Geriatric Oncology 1, 2, 3

The American Geriatrics Society implicitly recommends baseline renal function documentation and monitoring, as well as ensuring no concurrent nephrotoxic medications, when considering meloxicam use in elderly patients with moderate renal impairment 1, 2
Do not rely on serum creatinine alone, as it may mask significant renal impairment given age-related muscle mass loss, and do not assume "selective COX-2 inhibitors are safer" - meloxicam still carries nephrotoxicity risk in vulnerable populations, as stated by the International Society of Geriatric Oncology 1, 2